Follow
hardev Pandha
hardev Pandha
Professor of Medical Oncology University of Surrey
Verified email at surrey.ac.uk
Title
Cited by
Cited by
Year
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ...
Nature genetics 50 (7), 928-936, 2018
7602018
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the …
RF Gabitass, NE Annels, DD Stocken, HA Pandha, GW Middleton
Cancer Immunology, Immunotherapy 60, 1419-1430, 2011
6732011
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
AA Al Olama, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, ...
Nature genetics 46 (10), 1103-1109, 2014
5202014
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
A Samson, KJ Scott, D Taggart, EJ West, E Wilson, GJ Nuovo, S Thomson, ...
Science translational medicine 10 (422), eaam7577, 2018
3632018
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ...
Nature genetics 53 (1), 65-75, 2021
2972021
Measles virus causes immunogenic cell death in human melanoma
OG Donnelly, F Errington-Mais, L Steele, E Hadac, V Jennings, K Scott, ...
Gene therapy 20 (1), 7-15, 2013
2122013
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients
RA Adair, V Roulstone, KJ Scott, R Morgan, GJ Nuovo, M Fuller, D Beirne, ...
Science translational medicine 4 (138), 138ra77-138ra77, 2012
2052012
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
J Qiao, H Wang, T Kottke, C White, K Twigger, RM Diaz, J Thompson, ...
Clinical Cancer Research 14 (1), 259-269, 2008
2012008
Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses
K Rajani, C Parrish, T Kottke, J Thompson, S Zaidi, L Ilett, KG Shim, ...
Molecular Therapy 24 (1), 166-174, 2016
1922016
Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types
SP Kar, J Beesley, A Amin Al Olama, K Michailidou, J Tyrer, ZS Kote-Jarai, ...
Cancer discovery 6 (9), 1052-1067, 2016
1852016
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts
TM Seibert, CC Fan, Y Wang, V Zuber, R Karunamuni, JK Parsons, ...
bmj 360, 2018
1762018
Immunotherapeutic potential of whole tumour cells
S Ward, D Casey, MC Labarthe, M Whelan, A Dalgleish, H Pandha, ...
Cancer Immunology, Immunotherapy 51, 351-357, 2002
1742002
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other …
JB Bartlett, A Michael, IA Clarke, K Dredge, S Nicholson, H Kristeleit, ...
British journal of cancer 90 (5), 955-961, 2004
1682004
The biology of the sodium iodide symporter and its potential for targeted gene delivery
M Hingorani, C Spitzweg, G Vassaux, K Newbold, A Melcher, H Pandha, ...
Current cancer drug targets 10 (2), 242-267, 2010
1592010
Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer
R Morgan, A Boxall, A Bhatt, M Bailey, R Hindley, S Langley, HC Whitaker, ...
Clinical Cancer Research 17 (5), 1090-1098, 2011
1572011
E‐cadherin expression in bladder cancer using formalin‐fixed, paraffin‐embedded tissues: correlation with histopathological grade, tumour stage and survival
KN Syrigos, T Krausz, J Waxman, H Pandha, G Rowlinson‐Busza, ...
International journal of cancer 64 (6), 367-370, 1995
1521995
Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables
A Michael, G Ball, N Quatan, F Wushishi, N Russell, J Whelan, ...
Clinical cancer research 11 (12), 4469-4478, 2005
1462005
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
B Sirohi, R Powles, J Treleaven, P Mainwaring, S Kulkarni, H Pandha, ...
Bone marrow transplantation 25 (5), 533-539, 2000
1442000
Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients
E Derhovanessian, V Adams, K Hähnel, A Groeger, H Pandha, S Ward, ...
International journal of cancer 125 (6), 1372-1379, 2009
1432009
Large-scale transcriptome-wide association study identifies new prostate cancer risk regions
N Mancuso, S Gayther, A Gusev, W Zheng, KL Penney, Z Kote-Jarai, ...
Nature communications 9 (1), 4079, 2018
1362018
The system can't perform the operation now. Try again later.
Articles 1–20